SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Classic TA Workplace -- Ignore unavailable to you. Want to Upgrade?


To: Shack who wrote (65738)2/8/2003 1:29:14 AM
From: Grandk  Respond to of 209892
 
Wow, that belongs on a new thread entitled, "When TA goes bad, very bad".



To: Shack who wrote (65738)2/8/2003 6:39:21 AM
From: sa-mule  Respond to of 209892
 
Standard & Poor's health-care analyst Herman Saftlas upheld an "accumulate" rating on Johnson & Johnson (JNJ: news, board) late Friday. Amid a rumored $2 billion purchase of biotech drug company Scios (SCIO: news, board), Saftlas said an acquisition would provided much-needed new products. In Friday's after-hours trading, Scios continued its regular-session surge.

sam



To: Shack who wrote (65738)2/8/2003 9:43:49 AM
From: John Madarasz  Read Replies (1) | Respond to of 209892
 
Thxs for that, i think it will be a great study of an actionable stock at an apex point of a formation... and it could be a nice trade here too

stockcharts.com

AMGN has another couple weeks to go if it were to travel to the apex of it's wedge